CoChat

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

Open access
Carol, Hernan, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Billups, Catherine A., Geier, Brian, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A., Lock, Richard B. · 2013 · Pediatric Blood & Cancer
Cited by 65

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: RG7112 is a selective inhibitor of p53‐MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies. Procedures: RG7112 and its inactive enantiomer RG7112i were evaluated against the 23 cell lines of the PPTP in vitro panel using 96 hours exposure (1 nM to 10 µM). It was tested against the PPTP in vivo panel focusing on p53 wild‐type (WT) xenografts at a dose of 100 mg/kg daily for 14 days followed by 4 weeks of observation. Response outcomes were related to MDM2 and p53 expression datasets (http://pptp.nchresearch.org/data.html). Results: RG7112 demonstrated cytotoxic activity with a lower median IC 50 for p53 WT versus p53 mutant cell lines (approximately 0.4 µM vs. >10 µM, respectively). RG7112 induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C > 2) in 10 of 26 (38%) solid tumor xenografts. Objective responses included medulloblastoma, alveolar rhabdomyosarcoma, Wilms, rhabdoid and Ewing sarcoma xenografts. For the ALL panel, there was one partial response, five complete responses and one maintained complete response. The ALL xenografts expressed the highest levels of p53 among the PPTP panels. Conclusions: RG7112 induced tumor regressions in solid tumors from different histotype panels, and exhibited consistent high‐level activity against ALL xenografts. This high level of activity supports prioritization of RG7112 for further evaluation. Pediatr Blood Cancer 2013; 60: 633–641. © 2012 Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.24235

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 65

Metadata

Authors
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., & Lock, R. B.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2012-07-02
Volume
60
Issue
4
Pages
633-641
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W2134599660
Cited by
65
References
15
FWCI
3.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. https://app.cochat.ai/papers/10.1002/pbc.24235
The paper
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., & Lock, R. B. (2013). Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.24235

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.